Manufacturing and Access to Vaccines, medicines & health technology products in Africa (MAV+)

The EU's MAV+ initiative sits at an early and opaque stage. According to EU sources, the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies works with African partners to strengthen local pharmaceutical systems and manufacturing capacity across five countries, but the specific partner countries have not been publicly disclosed in available materials. The project is listed at Phase 2 of 5, meaning an agreement has been signed, but no financial figures have been made public. There are no records in the IATI Datastore confirming committed or disbursed EU funds, and no matching entries in the EIB project database. In practical terms, this means there is currently no independently verifiable financial trail for MAV+. Independent news coverage retrieved for this report does not directly reference the MAV+ initiative by name. The closest relevant developments concern parallel efforts by other institutions. In May 2026, the World Bank launched the Africa Initiative for Medical Access and Manufacturing (AIM2030), a distinct but thematically overlapping programme aimed at reducing the continent's dependence on imported medicines and building local production capacity. A landscape analysis published in The Lancet in February 2026 documented significant structural gaps in Africa's vaccine ecosystem, including fragmented regulation, limited clinical trial infrastructure, and constrained manufacturing readiness. These findings provide useful context for assessing what MAV+ is working against, though they do not speak to the EU initiative's progress specifically. The absence of independent reporting on MAV+ itself is notable. It may reflect the project's early phase, the regional rather than country-specific framing making it harder for journalists to track, or simply limited public disclosure by the EU institutions involved.